StockData

PAVmed vs Profusa

PAVM and PFSA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PAVM and PFSA compare

PAVmed is the larger company, worth 261 times as much as Profusa ($14.0M against $53.7K).

PAVmed scores higher on the StockData Score (6 against 0 for Profusa), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPAVMPFSA
Size and price
Market cap$14.0M$53.7K
Share price$1.75$0.406
Change, 1 year−83.5%−100.0%
Change, 5 years−99.9%–
Beta (5Y)1.263.11
Employees3–
StockData Score
Total score6 (better)0
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score4 (better)0
Dividend score00
Valuation
P/S125×–
P/B0.4×–
FCF yield−55.6%–
Growth
Revenue growth (TTM)−89.0%–
Net income growth (TTM)−117%–
Profitability
Gross margin−221%–
Operating margin−23843%–
Net margin−10795%–
FCF margin−6948%–
Return on equity−33.3%–
Return on invested capital−65.1%–
Financial health
Debt / equity0.00–
Interest coverage−3338.0×−136.6× (better)
Current ratio1.19 (better)0.03
Altman Z-score−10.97 (better)−364.70
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions11.7%25.3%
Held by insiders23.5%–
Insider net buying, 12 months–−$116K
Short interest, % of float0.21%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.